Chongqing Pharscin Pharmaceutical Becomes Marketing Authorization Holder for Clopidogrel Bisulfate Tablets

Stock News

Sep 27

Chongqing Pharscin Pharmaceutical Co.,Ltd. (002907.SZ) has announced that the company completed the change of its Pharmaceutical Production License for Clopidogrel Bisulfate Tablets in July 2026, and recently received the Drug Supplementary Application Approval Notice issued by the National Medical Products Administration for this product, marking the completion of the drug marketing authorization holder change, with the company now becoming its marketing authorization holder.

Clopidogrel Bisulfate Tablets is a commonly used antiplatelet aggregation drug in clinical practice, classified as a National Medical Insurance (Category B) drug and a National Essential Medicine. It is clinically used primarily for the prevention and treatment of heart, brain, and other arterial circulatory disorders caused by high platelet aggregation, such as recent-onset stroke, myocardial infarction, and confirmed peripheral arterial disease.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/news/1100419911"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1100419911\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1100419911?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-27 17:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1100419911","market":"hk","top_or_hot":-1,"title":"Chongqing Pharscin Pharmaceutical Becomes Marketing Authorization Holder for Clopidogrel Bisulfate Tablets","media":"Stock News","content":"<p>Chongqing Pharscin Pharmaceutical Co.,Ltd. (002907.SZ) has announced that the company completed the change of its Pharmaceutical Production License for Clopidogrel Bisulfate Tablets in July 2026, and recently received the Drug Supplementary Application Approval Notice issued by the National Medical Products Administration for this product, marking the completion of the drug marketing authorization holder change, with the company now becoming its marketing authorization holder.<br><br>Clopidogrel Bisulfate Tablets is a commonly used antiplatelet aggregation drug in clinical practice, classified as a National Medical Insurance (Category B) drug and a National Essential Medicine. It is clinically used primarily for the prevention and treatment of heart, brain, and other arterial circulatory disorders caused by high platelet aggregation, such as recent-onset stroke, myocardial infarction, and confirmed peripheral arterial disease.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chongqing Pharscin Pharmaceutical Becomes Marketing Authorization Holder for Clopidogrel Bisulfate Tablets</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChongqing Pharscin Pharmaceutical Becomes Marketing Authorization Holder for Clopidogrel Bisulfate Tablets\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-09-27 17:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Chongqing Pharscin Pharmaceutical Co.,Ltd. (002907.SZ) has announced that the company completed the change of its Pharmaceutical Production License for Clopidogrel Bisulfate Tablets in July 2026, and recently received the Drug Supplementary Application Approval Notice issued by the National Medical Products Administration for this product, marking the completion of the drug marketing authorization holder change, with the company now becoming its marketing authorization holder.<br><br>Clopidogrel Bisulfate Tablets is a commonly used antiplatelet aggregation drug in clinical practice, classified as a National Medical Insurance (Category B) drug and a National Essential Medicine. It is clinically used primarily for the prevention and treatment of heart, brain, and other arterial circulatory disorders caused by high platelet aggregation, such as recent-onset stroke, myocardial infarction, and confirmed peripheral arterial disease.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IPOS","symbol_name":"Renaissance International IPO ETF","start_time":0,"source_url":"","article_id":"1100419911","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1100419911","pubTimestamp":1790501890,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Chongqing Pharscin Pharmaceutical Co.,Ltd. (002907.SZ) has announced that the company completed the change of its Pharmaceutical Production License for Clopidogrel Bisulfate Tablets in July 2026, and...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IPOS":"Renaissance International IPO ETF","002907":"华森制药","BK0239":"医药制造"},"translate_title":"重庆医药成为硫酸氢氯吡格雷片上市许可持有人","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IPOS":1,"002907":1},"content_text":"Chongqing Pharscin Pharmaceutical Co.,Ltd. (002907.SZ) has announced that the company completed the change of its Pharmaceutical Production License for Clopidogrel Bisulfate Tablets in July 2026, and recently received the Drug Supplementary Application Approval Notice issued by the National Medical Products Administration for this product, marking the completion of the drug marketing authorization holder change, with the company now becoming its marketing authorization holder.Clopidogrel Bisulfate Tablets is a commonly used antiplatelet aggregation drug in clinical practice, classified as a National Medical Insurance (Category B) drug and a National Essential Medicine. It is clinically used primarily for the prevention and treatment of heart, brain, and other arterial circulatory disorders caused by high platelet aggregation, such as recent-onset stroke, myocardial infarction, and confirmed peripheral arterial disease.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}